



---

# **E-PROCEEDING BOOK**

**The 18<sup>th</sup> Annual Scientific Meeting on Pharmacology & Therapy**  
**Theme: Update in pharmacology: recent development in**  
**drug treatment and clinical management**  
**(virtual by zoom) December 5,6,11,12, 2020**

---



**Perhimpunan Dokter Spesialis Farmakologi Klinik (PERDAFKI)**  
**Yayasan Pengembangan Farmakologi & Terapi**



## SCIENTIFIC PROGRAM

### Day-1 (Friday) 4 December 2020

Description	
08.50-09.00	Opening remarks
09.00-09.30	Lecture 1 Mod: dr. Wawaimuli Arozal, M.Biomed, Ph.D
09.00-09.20	- <b>The ethical aspects in collaboration between medical doctors and industries in advertisement</b> Prof. Dr. dr. Rianto Setiabudy, Sp.FK
09.20-09.30	- Discussion
09.35-10.35	Symposium 1: <b>Update in nutrition practice in critical illness</b> Mod: Prof. Dr. dr. Purwastyastuti, M.Sc, Sp.FK
09.35-09.55	- <b>Strengthening link in nutrition therapy: role of trace element</b> dr. Fiasuti Witjaksono, Sp.GK
09.55-10.15	- <b>Management of nutrition therapy in acute illness</b> dr. Vera Irawany, Sp.AnKIC
10.15-10.35	- Discussion
10.40-11.40	Symposium 2: <b>Antimicrotubulin agent for cancer treatment</b> Mod: dr. Nafrialdi, Ph.D, Sp.PD
10.40-11.00	- <b>The role of antimicrotubulin agent: focus on eribulin in cancer therapy</b> Prof. Dr. dr. Rianto Setiabudy, Sp.FK
11.00-11.20	- <b>Eribulin treatment in soft tissue sarcoma, beyond first line: case sharing</b> dr. Nadia Ayu Mulansari, Sp.PD-KHOM
11.20-11.40	- Discussion
11.40-13.00	Friday prayer and break
13.00-14.00	Symposium 3: <b>The new era in gout management</b> Mod: Dr. dr. Anggi Gayatri, Sp.FK
13.00-13.20	- <b>Clinical approach and management of hyperuricemia and gout arthritis</b> dr. Anna Ariane, Sp.PD-KR
13.20-13.40	- <b>Current treatment options in gout management</b> Prof. Dr. dr. Rianto Setiabudy, Sp.FK
13.40-14.00	- Discussion

### Day-2 (Saturday) 5 December 2020

Description	
09.00-09.30	Research presentation 1 Mod: dr. Wawaimuli Arozal, M.Biomed, Ph.D <b>Development, characterization and pharmacokinetic profile of curcumin nanoparticles</b> Dr. Ni Made Dwi Sandhiutami, S.Si, M.Kes

09.40-10.40	Symposium 4: <b>Prediabetes &amp; thyroid disorders management: an update</b> Mod: Dr. dr. Dewi Selvina Rosdiana, M.Kes
09.40-10.00	- <b>The legacy of Metformin: from prevention to treatment of diabetes type 2</b> Prof. Dr. dr. Pradana Soewondo, SpPD-KEMD
10.00-10.20	- <b>70 years of Levotyroxine: in treating various faces of hypothyroidism: what should we know?</b> Prof. Dra. Arini Setiawati, Ph.D
10.20-10.40	- Discussion
10.50-11.50	Symposium 5: <b>From safety to benefit: the unexpected legacy of T2D CVOTs</b> Mod: dr. Zunilda Dj. Sadikin, MS, Sp.FK
10.50-11.10	- <b>New perspectives on recent cardiovascular outcome trial focus on Empagliflozin</b> Prof. Dra. Arini Setiawati, Ph.D
11.10-11.30	- <b>Cost-effectiveness of Empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk</b> Prof. Dr. Dra. Erna Kristin, Apt, M.Si
11.30-11.50	- Discussion
11.50-13.00	Break
13.00-14.00	Symposium 6: <b>The novel targeted therapy in differentiated thyroid carcinoma</b> Mod: dr. Vivian Soetikno, Ph.D, Sp.FK
13.00-13.20	- <b>Perspective in the use of Lenvatinib in differentiated thyroid carcinoma</b> Prof. Dra. Arini Setiawati, Ph.D
13.20-13.40	- <b>Lenvatinib: the new targeted therapy for differentiated thyroid carcinoma: case sharing</b> dr. Eko Purnomo, Sp.KNTM(K)
13.40-14.00	- Discussion

### Day-3 (Friday) 11 December 2020

Description	
09.00-09.30	Lecture 2 Mod: dr. Instiaty, Ph.D, Sp.FK
09.00-09.20	- <b>The role of clinical pharmacology in patient safety</b> dr. Nafrialdi, Ph.D, Sp.PD
09.20-09.30	- Discussion
09.35-10.35	Symposium 7: <b>Setting the roadmap of immunotherapy as the standard of care in advanced cancer management</b> Mod: Prof. Dr. dr. Rianto Setiabudy, Sp.FK
09.35-09.55	- <b>Role of immunotherapy in advanced cancer management</b> Prof. Dr. dr. Aru W. Sudoyo, Sp.PD, KHOM, FACP, FINASIM
09.55-10.15	- <b>How is the economic values of Pembrolizumab: focus in NSCLC</b>

10.15-10.35	Prof. Dr. Dra. Erna Kristin, Apt, M.Si - Discussion
10.40-11.40	Symposium 8: <b>Obesity: a reality check</b> Mod: dr. Instiaty, Ph.D, Sp.FK
10.40-11.00	- <b>Burdens and challenges of overweight and obesity</b> Prof. Dr. dr. Rianto Setiabudy, Sp.FK
11.00-11.20	- <b>Management of overweight and obesity</b> Prof. Dr. dr. Pradana Soewondo, Sp.PD-KEMD
11.20-11.40	- Discussion
11.40-13.00	Friday prayer and break
13.00-14.00	Symposium 9: <b>Innovative treatment paradigms in diabetes management: insulin innovation</b> Mod: Prof. Dr. dr. Armen Muchtar, Sp.FK
13.00-13.20	- <b>Rational therapy with basal insulin in type 2 diabetes mellitus patients according to the Guideline 2019</b> Prof. Dr. dr. Sarwono Waspadji, Sp.PD-KEMD
13.20-13.40	- <b>Better diabetes control with novel basal insulin: a real world solution</b> Prof. Dr. dr. Pradana Soewondo, Sp.PD-KEMD
13.40-14.00	- <b>Case based and diabetes patient profile with insulin glargine 300</b> Dr. dr. Tri Juli Edi Tarigan, Sp.PD-KEMD
14.00-14.30	- Discussion

#### Day-4 (Saturday) 12 December 2020

Description	
09.00-09.30	Research presentation 2 Mod: dr. Instiaty, Ph.D, Sp.FK <b>Pharmacometrics: alternative approach of quantitative pharmacology</b> Dr. dr. Anggi Gayatri, Sp.FK
09.40-10.40	Symposium 10: <b>The role of CCBs in hypertension</b> Mod: Dr. Dra. Ari Estuningtyas, M.Biomed
09.40-10.00	- <b>Disease and Guideline InaSH</b> Prof. Dr. dr. Rianto Setiabudy, Sp.FK
10.00-10.20	- <b>Adalat Oros: not all CCBs are equal</b> Prof. Dra. Arini Setiawati, PhD
10.20-10.40	- Discussion
10.50-11.50	Symposium 11: <b>Reframing asthma care</b> Mod: Prof. dr. Frans D. Suyatna, Ph.D, Sp.FK
10.50-11.10	- <b>Importance of antiinflammatory: a paradigm shift in asthma management</b> dr. Triya Damayanti, Ph.D, Sp.P(K)
11.10-11.30	- <b>Asthma exacerbation management update-the science of inhaled corticosteroid</b>

Description	
11.30-11.50	dr. Budhi Antariksa, Ph.D, Sp.P(K) - Discussion
11.50-13.00	Break
13.15-15.00	E-poster and discussion:
13.15-13.30	✓ Pengaruh pemberian suplemen berbahan kedelai terhadap sensitivitas insulin pada diabetes melitus tipe 2 ( <b>Ahmad Edy Purwoko</b> ).
13.30-13.45	✓ Ekstrak buah pare ( <i>Momordica charantia</i> ) meningkatkan jumlah sel beta pankreas tikus putih ( <i>Rattus norvegicus</i> ) wistar yang diinduksi streptozotosin ( <b>Arista Lestiyani, M. Fadhol Romdhoni, Yenni Bahar</b> ).
13.45-14.00	✓ Antimicrobial effect of Lemongrass ( <i>Cymbopogon citratus</i> ) and Ginger ( <i>Zingiber officinale</i> ) essential oils against nosocomial infection pathogens ( <b>Fanny Budiman, Lonah, Andy Setiawan, Stefanus Lembar</b> ).
14.00-14.15	✓ Farmakogenomik: pendekatan farmakologi menuju <i>personalized medicine</i> ( <b>Jefman Efendi Marzuki HY, Anggi Gayatri</b> ).
14.15-14.30	✓ Efektivitas penggunaan nifedipin sebagai tokolitik pada ancaman persalinan prematur ( <b>Nevi Sulvita Karsa, Peter Kabo, Natsir Djide, Nasruddin AM, Burhanuddin Bahar</b> ).
14.30-14.45	✓ Efek antibakteri madu hitam local Apis cerana terhadap <i>Staphylococcus aureus</i> secara in vitro ( <b>Rizaldy Lukman Parmana, Ferina Angelia, Fendra Wician</b> ).
14.45-15.00	✓ Potensi interaksi obat antibiotik pada pasien pneumonia di instalasi rawat inap Rumah Sakit "A" Pekanbaru ( <b>Syilfia Hasti, Tiara Tri Agustini, Afriyani Fitri</b> ).
15.00	Closing

## **Farmakogenomik: Pendekatan Farmakologi Menuju *Personalised Medicine***

**Jefman Efendi Marzuki HY<sup>1,2</sup>, Gayatri A<sup>3</sup>**

<sup>1</sup>Program Pendidikan Dokter Spesialis Farmakologi Klinik, FK UI, Jakarta

<sup>2</sup>Departemen Farmakologi, Fakultas Kedokteran Universitas Surabaya, Surabaya

<sup>3</sup>Departemen Farmakologi dan Terapeutik, FK UI, Jakarta

### **Abstrak**

Variabilitas respon obat antar pasien merupakan salah satu penyebab morbiditas dan mortalitas pada pasien. Sebagian pasien dapat mengalami *adverse drug reaction* (ADR) maupun efek subterapeutik pada pemberian obat. Terdapat beberapa faktor yang berkontribusi terhadap hal tersebut, salah satunya adalah variabilitas genetik antar individu. Variabilitas genetik tersebut mendorong perkembangan ilmu farmakogenomik saat ini. Farmakogenomik adalah ilmu yang mempelajari bagaimana gen memengaruhi respon individu terhadap obat. Tujuan dikembangkannya farmakogenomik adalah untuk menghasilkan pengobatan yang lebih optimal. Beberapa gen telah dibuktikan memiliki keterkaitan terhadap respon obat, yang mana dapat mempengaruhi kadar obat di dalam darah (farmakokinetik) maupun efek obat secara langsung (farmakodinamik). Perubahan farmakokinetik dan farmakodinamik obat dapat berpotensi menyebabkan toksisitas maupun penurunan efektivitas suatu obat. Tulisan ini bertujuan untuk memaparkan ketersediaan informasi variasi genetik yang telah diketahui dapat mempengaruhi respon obat, sehingga dapat membantu meningkatkan ketepatan strategi farmakoterapi.